Michael Smyth is the Division President and Corporate VP of TransPerfect's Life Science Solutions division, including the Trial Interactive platform and its solutions. Smyth has over 20 years of experience working in the pharmaceutical clinical development industry. Prior experience includes clinical and vaccine development at Teva Pharmaceuticals, Merck, Quintiles, and Premier Research managing large global phase III international trials that have resulted in the approval of products including Daytrana and Focalin for ADHD, Copaxone for Multiple Sclerosis, and others. He has also spent over five years in clinical technology and services solutions supporting life sciences companies on a global basis with a strategic goal to move towards a paperless clinical development environment. Michael consults with our pharmaceutical, biotechnology, medical device, and CRO clients to determine how to most efficiently use our Trial Interactive platform to streamline clinical development processes for all stakeholders. Smyth is an active member of the Drug Information Association as well as several clinical technology forums and has spoken at industry conferences on the multicultural challenges and solutions in conducting global clinical trials.